questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Protein-Serine-Threonine Kinases
Mitogen-Activated Protein Kinases
Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Mitogen-Activated Protein Kinase 3 : Questions médicales les plus fréquentes",
"headline": "Mitogen-Activated Protein Kinase 3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Mitogen-Activated Protein Kinase 3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-24",
"dateModified": "2025-02-18",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Extracellular Signal-Regulated MAP Kinases",
"url": "https://questionsmedicales.fr/mesh/D048049",
"about": {
"@type": "MedicalCondition",
"name": "Extracellular Signal-Regulated MAP Kinases",
"code": {
"@type": "MedicalCode",
"code": "D048049",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.563.567.249"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Mitogen-Activated Protein Kinase 3",
"alternateName": "Mitogen-Activated Protein Kinase 3",
"code": {
"@type": "MedicalCode",
"code": "D048052",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Juan Wang",
"url": "https://questionsmedicales.fr/author/Juan%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Division of Integrative Bioscience and Biotechnology, College of Life Sciences, Sejong University, Seoul 05006, Republic of Korea."
}
},
{
"@type": "Person",
"name": "Mohammad Shafiq",
"url": "https://questionsmedicales.fr/author/Mohammad%20Shafiq",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Kumaravelu Jagavelu",
"url": "https://questionsmedicales.fr/author/Kumaravelu%20Jagavelu",
"affiliation": {
"@type": "Organization",
"name": "From the Division of Pharmacology (M.S., K.J., K.H.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Neeraj Kumar Verma",
"url": "https://questionsmedicales.fr/author/Neeraj%20Kumar%20Verma",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
},
{
"@type": "Person",
"name": "Jimut Kanti Ghosh",
"url": "https://questionsmedicales.fr/author/Jimut%20Kanti%20Ghosh",
"affiliation": {
"@type": "Organization",
"name": "Division of Molecular and Structural Biology (N.K.V., J.K.G.), CSIR-Central Drug Research Institute, Lucknow, India."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Prediction of visual field progression in glaucoma: existing methods and artificial intelligence.",
"datePublished": "2023-08-04",
"url": "https://questionsmedicales.fr/article/37540325",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10384-023-01009-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Novel Visual Field Screening Program for Glaucoma With a Head-Mounted Perimeter.",
"datePublished": "2023-02-28",
"url": "https://questionsmedicales.fr/article/36847662",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/IJG.0000000000002199"
}
},
{
"@type": "ScholarlyArticle",
"name": "Teleglaucoma Using a New Smartphone-Based Tool for Visual Field Assessment.",
"datePublished": "2022-11-29",
"url": "https://questionsmedicales.fr/article/36730078",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/IJG.0000000000002153"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differences in eccentricity for sound-induced flash illusion in four visual fields.",
"datePublished": "2022-11-17",
"url": "https://questionsmedicales.fr/article/36397675",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/03010066221136670"
}
},
{
"@type": "ScholarlyArticle",
"name": "Iridotomy to slow progression of visual field loss in angle-closure glaucoma.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36621864",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD012270.pub3"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protein-Serine-Threonine Kinases",
"item": "https://questionsmedicales.fr/mesh/D017346"
},
{
"@type": "ListItem",
"position": 6,
"name": "Mitogen-Activated Protein Kinases",
"item": "https://questionsmedicales.fr/mesh/D020928"
},
{
"@type": "ListItem",
"position": 7,
"name": "Extracellular Signal-Regulated MAP Kinases",
"item": "https://questionsmedicales.fr/mesh/D048049"
},
{
"@type": "ListItem",
"position": 8,
"name": "Mitogen-Activated Protein Kinase 3",
"item": "https://questionsmedicales.fr/mesh/D048052"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Mitogen-Activated Protein Kinase 3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Mitogen-Activated Protein Kinase 3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Mitogen-Activated Protein Kinase 3",
"description": "Comment diagnostiquer une dysfonction de MAPK3 ?\nQuels tests sont utilisés pour évaluer MAPK3 ?\nY a-t-il des biomarqueurs associés à MAPK3 ?\nMAPK3 est-elle impliquée dans des maladies spécifiques ?\nQuels symptômes peuvent indiquer un problème avec MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Mitogen-Activated Protein Kinase 3",
"description": "Quels symptômes sont liés à une activation excessive de MAPK3 ?\nMAPK3 affecte-t-elle le système immunitaire ?\nQuels signes cliniques sont associés à MAPK3 ?\nY a-t-il des symptômes neurologiques liés à MAPK3 ?\nComment la MAPK3 influence-t-elle le stress cellulaire ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Mitogen-Activated Protein Kinase 3",
"description": "Comment prévenir les dysfonctionnements de MAPK3 ?\nY a-t-il des habitudes à éviter pour MAPK3 ?\nLe stress peut-il affecter MAPK3 ?\nDes exercices spécifiques aident-ils MAPK3 ?\nLa gestion du poids influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Mitogen-Activated Protein Kinase 3",
"description": "Quels traitements ciblent MAPK3 ?\nLa thérapie génique peut-elle corriger MAPK3 ?\nQuels médicaments affectent la voie MAPK3 ?\nY a-t-il des traitements naturels pour MAPK3 ?\nComment la nutrition influence-t-elle MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Mitogen-Activated Protein Kinase 3",
"description": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?\nMAPK3 est-elle liée à des maladies auto-immunes ?\nComment MAPK3 affecte-t-elle le cancer ?\nY a-t-il des risques cardiovasculaires liés à MAPK3 ?\nMAPK3 peut-elle influencer le vieillissement ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Mitogen-Activated Protein Kinase 3",
"description": "Quels facteurs de risque sont associés à MAPK3 ?\nL'âge influence-t-il l'activité de MAPK3 ?\nY a-t-il des prédispositions génétiques pour MAPK3 ?\nLe mode de vie influence-t-il MAPK3 ?\nDes infections peuvent-elles affecter MAPK3 ?",
"url": "https://questionsmedicales.fr/mesh/D048052?mesh_terms=Visual+Fields&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de MAPK3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de signalisation cellulaire peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer MAPK3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de phosphorylation et les analyses protéomiques sont courants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à MAPK3 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de certaines protéines peuvent indiquer une dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle impliquée dans des maladies spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est liée à des cancers et des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec MAPK3 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés selon la maladie, comme la fatigue ou des douleurs chroniques."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une activation excessive de MAPK3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive peut entraîner une inflammation et des douleurs."
}
},
{
"@type": "Question",
"name": "MAPK3 affecte-t-elle le système immunitaire ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle joue un rôle dans la régulation de la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à MAPK3 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des éruptions cutanées ou des troubles métaboliques peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques liés à MAPK3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles neurologiques peuvent survenir en cas de dysfonction de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la MAPK3 influence-t-elle le stress cellulaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle régule les réponses au stress, affectant la survie cellulaire et l'apoptose."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements de MAPK3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une bonne nutrition et de l'exercice, est recommandé."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes à éviter pour MAPK3 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le tabagisme et une alimentation riche en graisses saturées est conseillé."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter MAPK3 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut perturber la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Des exercices spécifiques aident-ils MAPK3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des exercices réguliers peuvent améliorer la régulation de MAPK3."
}
},
{
"@type": "Question",
"name": "La gestion du poids influence-t-elle MAPK3 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un poids santé peut aider à réguler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent MAPK3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques de MAPK3 sont en développement pour traiter certains cancers."
}
},
{
"@type": "Question",
"name": "La thérapie génique peut-elle corriger MAPK3 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est une approche potentielle pour corriger des mutations de MAPK3."
}
},
{
"@type": "Question",
"name": "Quels médicaments affectent la voie MAPK3 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les inhibiteurs de MEK peuvent moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour MAPK3 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales peuvent influencer la signalisation de MAPK3."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle MAPK3 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en antioxydants peut moduler l'activité de MAPK3."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dysfonction de MAPK3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme le cancer, l'inflammation chronique et des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "MAPK3 est-elle liée à des maladies auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans MAPK3 peuvent contribuer à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Comment MAPK3 affecte-t-elle le cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation aberrante de MAPK3 est souvent observée dans divers types de cancer."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques cardiovasculaires liés à MAPK3 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un lien entre MAPK3 et des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "MAPK3 peut-elle influencer le vieillissement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements de MAPK3 sont associés à des processus de vieillissement prématuré."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à MAPK3 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'obésité, le tabagisme et le stress sont des risques connus."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il l'activité de MAPK3 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'activité de MAPK3 peut diminuer avec l'âge, affectant la signalisation cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques pour MAPK3 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mutations génétiques peuvent prédisposer à des dysfonctionnements de MAPK3."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il MAPK3 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Des infections peuvent-elles affecter MAPK3 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales peuvent perturber la signalisation de MAPK3."
}
}
]
}
]
}
Timely treatment is essential in the management of glaucoma. However, subjective assessment of visual field (VF) progression is not recommended, because it can be unreliable. There are two types of ar...
A novel visual field screening program with a head-mounted perimeter 'imo' could detect glaucoma at all stages in a short time with high accuracy....
The present study aimed to examine the accuracy and availability of a novel glaucoma visual field screening program using a head-mounted visual perimeter 'imo.'...
Eyes of 76 non-glaucoma participants and 92 glaucoma patients were examined. All patients underwent visual field tests using the Humphrey Visual Field Analyzer (30-2 or 24-2 Swedish Interactive Thresh...
The sensitivity, specificity, positive predictive value, and negative predictive value of the visual field screening program were 76%-100%, 91%-100%, 86%-89%, and 79%-100%, respectively. The visual fi...
Visual field screening using a head-mounted perimeter 'imo' detected glaucoma at all stages in a short time with high accuracy....
COVID-19 underlines the importance of telemedical diagnostics. The smartphone-based campimetry (Sb-C) is a newly developed digital application allowing visual field testing using a head-mounted device...
Sb-C is a newly developed tool for functional ophthalmic diagnosis. This study aimed to examine the comparability of the Sb-C and Octopus 900 to ensure ophthalmological care in times of social distanc...
Total 93 eyes were included in the study. After an ophthalmological examination, the visual field was tested by the Octopus program G1 and by the smartphone-based campimeter. The Sb-C was performed us...
The group comprised 48 women and 45 men (mean age: 62.52±12.2 y) including 19 controls, 17 patients with ocular hypertension, 11 preperimetric glaucomas, and 46 perimetric glaucomas. The mean sensitiv...
With some technical adjustments, the Sb-C shows promise for screening glaucoma and monitoring disease progression remotely from an ophthalmologic clinic....
A sound-induced flash illusion (SiFI) is a multisensory illusion dominated by auditory stimuli, in which the individual perceives that the number of visual flashes is equal to the number of auditory s...
Primary angle-closure glaucoma is a type of glaucoma associated with a physically obstructed anterior chamber angle. For example, contact between the iris and lens at the pupillary margin creates a pu...
To assess the effects of iridotomy compared with no iridotomy for primary angle-closure glaucoma, primary angle-closure, and primary angle-closure suspect....
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 10), which contains the Cochrane Eyes and Vision Trials Register; MEDLINE Ovid; Embase Ovid; PubMed; LILACS; Clinic...
Randomized or quasi-randomized controlled trials that compared iridotomy with no iridotomy in primary angle-closure suspects, people with primary angle-closure, or people with primary angle-closure gl...
We used standard Cochrane methodology and assessed the certainty of the body of evidence for prespecified outcomes using the GRADE approach....
We identified four studies (3086 eyes of 1543 participants) that compared iridotomy with no iridotomy in participants (range of mean age 59.6 to 62.9 years) who were primary angle-closure suspects fro...
Individuals with homonymous visual field loss (HVFL) fail to perceive visual information that falls within the blind portions of their visual field. This places additional burden on memory to represen...
Functional gradients, in which response properties change gradually across the cortical surface, have been proposed as a key organising principle of the brain. However, the presence of these gradients...
Coordination of goal-directed behavior depends on the brain's ability to recover the locations of relevant objects in the world. In humans, the visual system encodes the spatial organization of sensor...
Contrast sensitivity (CS) is closely associated with vision-related quality of life in glaucoma patients. This cross-sectional study was performed to determine the relationship between CS and visual f...
Visual field loss is a common consequence of stroke and often precludes driving. However, legal visual requirements for drivers' licenses are largely without scientific basis....
This study aimed to examine the effects of different types of homonymous visual field loss after stroke on simulated driving....
Data on performance and safety from a traffic simulator test for 153 participants with withdrawn drivers' licenses due to visual field loss from stroke were retrospectively compared with data from 83 ...
Sixty-five percent of the stroke participants passed the simulator test (95% confidence interval, 57 to 72%). Younger patients were more successful than older. However, classification by neither type ...
In this large cohort, driver safety could not be predicted from the type of homonymous visual field loss. Even individuals with severe visual field loss might be safe drivers. Therefore, it seems reas...